Emerging role of N6-methyladenosine RNA modification in regulation of SARS-CoV-2 infection and virus-host interactions

Jiayi Liu; Lingli Chen; Xiongmin Guo; Bingrong Zhao; Juan Jiang

Biomedicine & Pharmacotherapy (Apr 2024)

Emerging role of N6-methyladenosine RNA modification in regulation of SARS-CoV-2 infection and virus-host interactions

Jiayi Liu,
Lingli Chen,
Xiongmin Guo,
Bingrong Zhao,
Juan Jiang

Affiliations

Jiayi Liu: Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha 410008, China
Lingli Chen: Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, China
Xiongmin Guo: Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha 410008, China
Bingrong Zhao: Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha 410008, China; Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha 410008, China; Hunan Engineering Research Center for Intelligent Diagnosis and Treatment of Respiratory Disease, Changsha 410008, China; Corresponding authors at: Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha 410008, China.
Juan Jiang: Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha 410008, China; Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha 410008, China; Hunan Engineering Research Center for Intelligent Diagnosis and Treatment of Respiratory Disease, Changsha 410008, China; Corresponding authors at: Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha 410008, China.

Journal volume & issue: Vol. 173
p. 116231

Abstract

Read online

Since December 2019, the infection caused by Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) has posed an enormous threat to human health security worldwide. Constant mutation of viral genome and varying therapeutic responses of patients infected with this virus prompted efforts to uncover more novel regulators in the pathogenesis. The involvement of N6-methyladenosine, a modified form of RNA, plays a crucial role in viral replication, viral pathogenicity, and intricate signaling pathways connected with immune responses. This review discusses research advances revealing the regulation of the life cycle of SARS-CoV-2 and antiviral responses of host cells by RNA m6A modification, highlights the biological functions of N6-methyladenosine components in SARS-CoV-2 infection and virus-host interactions, and outlines current challenges and future directions for exploring the potential clinical value of m6A modification in COVID-19.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords